PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, NON- RANDO MIZED, OPEN -LABEL STUDY TO ASSESS THE 
PHARMACOKINETICS, SAFETY AND TOLERABILIT Y OF PF -07321332 
BOOSTED WITH RITONAVIR IN ADULT PARTICIPANTS WITH MODERATE 
HEPATIC IMPAIRMENT AND HEALTHY PARTICIPANTS WITH NORMAL 
HEPATIC FUNCTION
Study Intervention Number : PF-07321332
Study Intervention Name: Not applicable
USIND Number: 153517
EudraCT Number: N/A
ClinicalTrials.gov ID: N/A
Protocol Number: C4671010
Phase: 1
Brief Title: Study  to Estimate the Effects of Hepatic I mpairment on the 
Pharmacokinetics of PF -07321332
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these document s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by appl icable law ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 25June 2021

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
LIST OF FIGURES ................................................................................................................ ...8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 12
1.3. Schedule of Activities .............................................................................................13
2. INTRODUCTION ...............................................................................................................1 6
2.1. Study R ationale .......................................................................................................16
2.2. Background .............................................................................................................16
2.2.1. Nonclinical Pharmacology..........................................................................162.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................162.2.3. Nonclinical Safety ......................................................................................172.2.4. Clinical Overview.......................................................................................17
2.3. Benefit/Risk Assessment.........................................................................................19
2.3.2. Benefit Assessment.....................................................................................22
2.3.3. Overall Benefit/Risk Conclusion................................................................22
3. OBJECTIVES AND ENDPOINTS .....................................................................................224. STUDY DESIGN................................................................................................................ .23
4.1. Overall Design.........................................................................................................234.2. Scientific Rationale for Study Design.....................................................................24
4.2.1. Choice of Contraception/Barrier Requirements .........................................254.2.2. Collection of Retained Research Samples..................................................25
4.3. Justification for Dose ..............................................................................................254.4. End of Study Definition ..........................................................................................25
5. STUDY POPULATION ......................................................................................................25
5.1. Inclusion Criteria.....................................................................................................26
5.2. Exclusion Criteria....................................................................................................27
5.3. Lifestyle Cons iderations..........................................................................................31CCI
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 45.3.1. Meals and Dietary  Restrictions ...................................................................31
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................31
5.3.3. Activity .......................................................................................................31
5.3.4. Contraception ..............................................................................................32
5.4. Screen Failures ........................................................................................................32
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................32
6.1. Study  Intervention(s) Administered ........................................................................32
6.1.1. Administration ............................................................................................33
6.2. Preparation, Handling, Storage, and Accountability ...............................................33
6.2.1. Preparation and Dispensing ........................................................................34
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................34
6.3.1. Allocation to Study Intervention ................................................................34
6.4. Study  Intervention Compliance ...............................................................................34
6.5. Dose Modification ...................................................................................................35
6.6. Conti nued Access to Study  Intervention After the End of the Study ......................35
6.7. Treatment of Overdose
............................................................................................35
6.8. Concomitant Therapy ..............................................................................................35
6.8.1. Participants with Healthy  Liver Function (Cohort 1) .................................36
6.8.2.
Participants with Impaired Liver Function (Cohort 2) ...............................36
6.8.3. Rescue Medicine .........................................................................................36
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................36
7.1. Discontinuation of Study  Intervention ....................................................................36
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......37
7.2.1. Withdrawal of Consent ................................ ................................ ............... 38
7.3. L ost to Follow up ....................................................................................................38
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 38
8.1. Efficacy  Assessments ..............................................................................................40
8.2. Saf ety Assessments .................................................................................................40
8.2.1. Phy sical Examinations ................................................................................40
8.2.2. Vital Signs ..................................................................................................40
8.2.3. Electrocardiograms
.....................................................................................41

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 58.2.4. Clinical Safety La boratory Asse ssments ....................................................41
8.2.5. COVID-19 specific assessments.................................................................428.2.6. Pregnancy Testing ......................................................................................42
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................43
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......43
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................448.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................44
8.3.2. Method of Detecting AEs and SAEs ..........................................................448.3.3. Follow-up of AEs and SAEs.......................................................................448.3.4. Regulatory Reporting Requirements for SAEs...........................................448.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................45
8.3.5.1. Exposure During Pregnancy......................................................458.3.5.2. Exposure During Breastfeeding ................................................478.3.5.3. Occupational Exposure .............................................................47
8.3.6. Cardiovascular and Death Events...............................................................478.3.7. Disease Related Events and/or Disease Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................47
8.3.8. Adverse Events of Special Interest.............................................................47
8.3.8.1. Lack of Efficacy........................................................................48
8.3.9. Medical Device Deficiencies......................................................................488.3.10. Medication Errors .....................................................................................48
8.4. Pharmacokinetics ....................................................................................................48
8.4.1. Plasma for Analysis of PF-07321332 ..................................48
8.7. Immunogenicity Assessments .................................................................................51CCI
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 68.8. Health Economics ...................................................................................................51
9. STATISTICAL C ONSIDERATIONS ................................................................................51
9.1. Statistical Hypotheses .............................................................................................519.2. Analysis Sets ...........................................................................................................519.3. Statistical Analyses .................................................................................................51
9.3.1. Other Safety Analyses ................................................................................52
9.3.2.1. Pharmacokinetic Analyses ........................................................52
9.4. Interim Analyses .....................................................................................................54
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................55
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............55
10.1.1. Regulatory and Ethical Considerations ....................................................55
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................55
10.1.2. Financial Disclosure .................................................................................5610.1.3. Informed Consent Process ........................................................................5610.1.4. Data Protection .........................................................................................5710.1.5. Committees Structure ...............................................................................57
10.1.5.1. Data Monitoring Committee ...................................................57
10.1.6. Dissemination of Clinical Study Data ......................................................5710.1.7. Data Qualit y Assurance ............................................................................58
10.1.8. Source Documents....................................................................................5910.1.9. Study and Site Start and Closure ..............................................................6010.1.10. Publication Policy...................................................................................6110.1.11. Sponsor’s Qualified Medical Personnel .................................................62
10.2. Appendix 2: Clinical Laboratory Tests .................................................................6310.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................64
10.3.1. Definition of AE .......................................................................................64
10.3.2. Definition of an SAE ................................................................................65CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 710.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................66
10.3.4. Reporting of SAEs....................................................................................70
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................72
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7210.4.2. Female Participant Reproductive Inclusion Criteria.................................7210.4.3. Woman of Childbearing Potential ............................................................7310.4.4. Contraception Methods.............................................................................74
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......77
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................79
10.9. Appendix 9: Child-Pugh Classification (CPC) of Liver Dysfunction...................84
10.10. Appendix 10: Abbreviations ...............................................................................85
11. REFERENCES ................................................................................................................. .89CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 8LIST OF TABLES
Table 1. Hepatic Function Categories Based on Child-Pugh Score .......................23Table 2. Plasma PK Parameters..............................................................................53
Table 4. Protocol-Required Safety Laboratory Assessments .................................63
Table 5. Scoring for Child-Pugh Classification......................................................84Table 6. Derivation of Child-Pugh Classification Score ........................................84Table 7. Determination of Encephalopathy Grade .................................................84
LIST OF FIGURES
Figure 1. Treatment and Schema .............................................................................12CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY 
1.1. Synopsis Brief Title: Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics of 
PF-07321332.
RationaleThe purpose of this study is to estimate the effect of hepatic impairment on the plasma PK of 
PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.
Objectives and Endpoints
Objectives Endpoints
Primary: Primary:
•To compare the PK of PF-07321332, following 
a single oral dose administration of 
PF-07321332 pharmacokinetically boosted with ritonavir in adult participants with moderate hepatic impairment and age and body weight-matched participants without hepatic impairment.•Plasma PF-07321332 PK parameters: C
max, 
AUC last, AUC inf (if data permit)
Secondary: Secondary: 
•To evaluate the safety and tolerability of 
PF-07321332 and ritonavir, following a single oral dose administration of PF-07321332 pharmacokinetically boosted with ritonavir, in participants with moderate hepatic impairment 
and in healthy participants with normal hepatic 
function.•Incidence of TEAEs, abnormal ECGs, vital signs, and laboratory values
 
 
 
 
 
 
 
 
  
 
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 10Overall Design
Brief SummaryThis is a Phase 1, non-randomized, open-label study to investigate the effect of hepatic 
impairment on the plasma PK, safety and tolerability of a single oral dose of PF-07321332 in combination with the PK boosting agent ritonavir in approximately 16 participants. The study will be conducted in adult participants with stable, moderate hepatic impairment and a control group of participants with normal hepatic function. 
Enrollment will be in a staged manner such that participants with hepatic impairment 
(Cohort 2) will begin enrollment first. Participants without hepatic impairment (Cohort 1) will begin recruitment towards the end of Cohort 2 or earlier, at the sponsor’s discretion such that the enrollment in both cohorts may overlap. Participants in Cohort 1 will match the average demographics (at a minimum, age and weight; gender and race as much as practically possible) of participants in Cohort 2. 
All participants in both cohorts will provide informed consent and undergo Screening 
evaluations to determine their eligibility. Categorization of participants into hepatic impairment cohort, Cohort 2, will be done based on Child-Pugh scores as described in Appendix 9 , at the Screening visit.
Participants who prematurely discontinue for non-safety related reasons may be replaced, at 
the discretion of the PI and sponsor study team.
Eligible participants will be admitted to the CRU on Day -1 (at least 12 hours prior to the 
dosing of PF-07321332 on Day 1) and will be confined in the CRU until Day 3. On the evening of Day -1, participants will receive a single 100 mg dose of ritonavir (-12 hour relative to PF-07321332 dosing). On the morning of Day 1, the participants will receive a single dose of 100 mg PF-07321332 with a 100 mg dose of ritonavir after an overnight (or a minimum of 6 hours) fast. Ritonavir, 100 mg, will continue to be dosed at 12 and 24 hours post PF-07321332 dosing to ensure maintenance of the PK boosting effect. Serial blood  
 samples at specified intervals will be collected up to 24 hours post-dose for PK 
assessments. 
Safety assessments will be performed during Screening, on Day -1 prior to dosing and on 
Day 3. Physical examinations, vital sign measurements, and clinical laboratory tests will be 
conducted, and AEs will be monitored to assess safety. The total participation time (eg, CRU 
confinement time for study procedures) for each participant in this study is approximately 3 nights/4 days (excluding screening & Follow-Up contact). 
A safety follow-up call will be made to participants 28 to 35 days from administration of the 
last dose of PF-07321332.
Number of ParticipantsApproximately 16 participants will be enrolled to study intervention.
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 11Note: "Enrolled" means a participant's, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screenin g. A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activity  after screening .Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
notparticipate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.
Intervention Groups and Duration
Each enrolled participant will receive a single 100 mg dose of PF -07321332 administered 
orally  in combination with the PK b
oosting agent ritonavir administered as a 100 mg dose 
at -12, 0, 12, and 24 hours relative to PF- 07321332 dosing. 
The total planned duration of participation, from the Screening visit to the last Follow -up 
phone call, is approximately  up to 9 weeks.
Data Monitoring Committee or Other Independent Oversight Committee : No
Statistical Methods
One-way ANOVA will be used to compare the natural log transformed AUC last, AUC inf(if 
data permit ) and C maxfor PF -
07321332 between Cohort 2with moderate hepatic impairment 
(Test) and Cohort 1with normal hepatic function (Reference) . Estimates of the adjusted 
mean differences (Test -Reference) and corresponding 90% CI will be obtained from the 
model. The adjusted mean differences and 90% CIs for the differences will be exponentiated 
to provide estimates of the ratio of the adjusted geometric means (Test/Reference) and 
90% CIs for the ratios.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 121.2.Schema
Figure 1
.Treatment and Schema
≤ 28 days
Screen
 Day -1
Admission to CRU
Administration of ritonavira
Day 1
Administration of PF -07321332 
and ritonavirb
Day 2
Last dose of ritonavirb
Day 3
CRU Discharge 
Inpatient Stay at CRU
Day 28 –35 
Follow -up via 
telephone contactc
a. Admission can occur at any time of day; once admitted, participants to be provided inpatient meal(s). On the 
evening of Day -1, participants will receive a single 100 mg dose of ritonavir ( -12-hour relative to PF -07321332 
dosing). 
b. On the morning of Day 1, participants will receive a single dose of 100 mg PF -
07321332 with a 100 mg dose of 
ritonavir after a fast of at least 6 hours, followed by ritonavir (100 mg) to be dosed at 12 and 24 hours post 
PF-07321332 dosing. 
c. Contact may occur via telephone contact and must occur 28 to 35 days from administration of PF- 07321332 or 
from the time of early termination/discontinuation. 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 131.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in additi on to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit IdentifieraScreening Day -1 Day 1 Day 2 Day 3 Early 
Termination/
DCFollow -up
Contact
Days Relative to Day 1
Abbreviations used in this table 
can be found in Appendix 10Day -28 to Day -2 28-35 Daysb
Informed consent X
Admission to CRU X
Confinement to CRU X   X
Inclusion/exclusion criteria X X
Medical history X X
DemographycX
Physical examinationdX X X X
Height and weight assessment X
Safety laboratory testseX X X X
Child -Pugh classificationfX
History of illegal 
drug/tobacco/alcohol useX X
Urine alcohol test or alcohol 
breath testX X
Urine or serum pregnancy test 
(WOCBP only)X X X X
Contraception checkgX X X X X
Serum FSH in post -menopausal 
females amenorrheic ≥12 months 
and under 60 years of ageX
Urine drug screen X X
Single supine 12-Lead ECGhX X X X

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 14Visit IdentifieraScreening Day -1 Day 1 Day 2 Day 3 Early 
Termination/
DCFollow-up
Contact
Days Relative to Day 1
Abbreviations used in this table 
can be found in Appendix 10Day -28 to Day -2 28-35 Daysb
Single, seated vital signs (BP, 
and pulse rate)iXXX X
HIV, HBsAg, HBcAb, HCVAb 
testingjX
PF-07321332 administration X
Ritonavir administrationkXXX
Plasma PK for PF-07321332  
lXXXX
 
Prior/concomitant treatments X X →→ XXX
COVID-19 testingoXX
COVID-19 check temperaturepXXXXX
COVID-19 questionnaireqXX
CRU discharge X
Serious and nonserious adverse 
event monitoringXX →→ XXX
Standard meals X XrXX
a. Day relative to start of PF-07321332 dosing (Day 1).
b. Contact may occur via telephone contact and must occur 28 to 35 days from administration of PF-07321332 or from the time of e arly termination/discontinuation. 
c. Demographics will include race, age, and gender.d. Complete physical examination will be performed at screening; and limited PE will be conducted on Day -1, Day 3, early termin ation, and at any time point as deemed 
necessary by the investigator.
e. Safety laboratory assessments include chemistry, hematology, and urinalysis (and microscopy, if needed) and must be collected following at least a 4 hour fast. 
f. The Child-Pugh classification ( Appendix 9 ) will be used to define the participants of Cohort 2 with moderate hepatic impairment (Child-Pugh Class B) at Screening.
g. Confirmation of the correct use
of appropriate contraceptive method.
h. Single 12-lead ECG readings will be taken pre-dose on Day 1 and at specified times. All ECG assessments will be made prior to  any blood draws or vital sign 
measurements. 
i. Single seated BP and PR will be performed pre-dose on Day 1 and at specified times. All BP and PR will be measured prior to co llection of blood draws if scheduled at the 
same time, after collection of ECGs.
j. Testing will be performed as described in Appendix 2 .CCICCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 15Visit IdentifieraScreening Day -1 Day 1 Day 2 Day 3 Early 
Termination/
DCFollow-up
Contact
Days Relative to Day 1
Abbreviations used in this table 
can be found in Appendix 10Day -28 to Day -2 28-35 Daysb
k. Ritonavir will be administered on Day -1 at -12 hours, Day 1 at 0 hours and 12 hours, and Day 2 at 24 hours, relative to PF-0 7321332 dosing.
l. Blood samples are to be collected for plasma PK assessment of PF-07321332  on Day 1 at 0 (pre-dose for PF-07321332), 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours, 
Day 2 at 24 and 36 hours, and Day 3 at 48 hours, relative to PF-07321332 dosing, and at early termination/DC (if before 48 hours pos t-dose for PF-07321332), if needed.
 
o. Testing for COVID-19 pathogen will be performed prior to being admitted to the clinic for confinement, on Day -1, and if part icipant develops COVID-19 like symptoms.
p. To be done at least daily during residence. q. Check exposure to positive case, residence or travel in area of high incidence and COVID-19 related signs and symptoms.
r. Meals/snacks to be served at clock times matching approximately 0H, 4H, 7H, 10H, and 14H (optional) relative to dosing on Day 1 (while inpatient).CCI
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 162.INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3CL  protease that is 
currentl y being developed as an oral treatment of COVID -19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious.
2.1.Study Rationale 
PF-07321332/ritonavir is intended for short term (eg, 5 day) use, in patients with COVI D-19,
some of whom may  have some degree of impaired hepatic function. Therefore, the purpo se 
of this study  is to characterize the effect of hepatic impairment on the plasma PK of 
PF-07321332/ritonavir. Findings from this study  will be used to develop dosing 
recommendations so that the dose and/or dosing interval may  be adjusted appropriatel y inthe 
presence of hepatic disease.
2.2.Background 
In December 2019, COVID -19 was identified as a new, potentially  fatal, respiratory  infection 
caused b y the novel coronavirus, SARS -CoV -2. The WHO declared COVID -
19 a Public 
Health Emergency  of International Concern on 20 January 2020 and further characterized the 
disease outbreak as a pandemic on 11 March 2020.1
PF-07321332 is an orall y bioavailable 3CLproinhibitor shown to be effective against 
SARS -CoV -23CLpro(Ki= 0.00311 µM) in a biochemical enzy matic assay . Since the 
3CLprofrom human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzy me, the ability  of PF -07321332 to inhibit the 3CLpro
of other coronavi ruses (SARS -CoV -1 and HCoV -229E, MERS, HCoV -OC43, HCoV -HKU1 , 
and HCoV -NL63) was also confirmed, indicating a potential for broad spectrum 
anti-coronavirus activity . The coronavirus 3CL  protease is a virall y encoded enzy me that is 
critical to the SARS- CoV -2replication cy cle, analogous to other obligatory  virally  encoded 
proteases (eg, HIV Protease, HCV Protease).2PF-07321332 is being developed as an oral 
treatment in patients with COVID -19 infection. 
Ritonavir is a strong CYP3A4 inhibitor being used to in hibit the metabolism of PF-07321332 
in order to increase plasma concentrations of PF -07321332 to values that are anticipated to 
be efficacious. R itonavir did not show SARS -CoV -2 antiviral activity  in vitro up to 3 µM 
ritonavir and is being used only  as a p harmacokinetic boosting agent.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology  of PF -07321332 can be found in the current IB.3
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Hepatic CYP450 enzy mes were identified as the main pathway  for clearance of PF -07321332 
in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey , and human), hepatocy tes 
(rat, monkey , and human), and in vivo in rat and monkey  after repeat oral dosing. In a 
reaction phenot yping study  using human liver microsom es in the presence of selective CYP
inhibitors, CYP3A4 was predicted to be the major contributor (f m= 0.99) to the in vitro 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 17oxidative metabolism of PF -07321332. No significant CYP3A5 contribution is expected to 
the metabolism of PF -07321332. Urinary  excre tion of PF -07321332 following single IV or 
oral doses in rats was approximately  11%, suggesting minor urinary  contributions to the 
overall elimination of PF-07321332.
PF-07321332 is not extensively  bound to human plasma proteins, with f uof 0.31 observed i n 
the in vitro protein binding stud y.
Additional information of the nonclinical PK and metabolism of PF -07321332 is available in 
the current IB.3
2.2.3. Nonclinical Safet y
There were no adverse findings observed in repeat- dose toxicity  studies in rats and monkey s 
up to 2 weeks duration and theNOAELs were the highest dose administered (1000 mg/kg 
and 600 mg/kg in the rat and monkey  studies, respectivel y). PF-07321332-related 
non-adverse, test article -related clinical findings included sporadic occurrence of emesis with 
slight body  weight decreases in monkey s. Monitorable and reversible clinical pathology  
findings included those possibly
 suggestive of low -grade inflamma tion (in rats and monkey s) 
or alterations in the coagulation pathway s (in rats only ) without clinical or microscopic 
correlates. Other non-adverse clinical pathology  findings were likel y due to the emesis and 
subsequent dehydration in monkeys. In rats administered 1000 mg/kg/day , lower mean 
absolute and relative heart weights (females) and higher absolute and relative liver weights 
(both sexes) were observed relative to controls. The lower heart weights had no microscopic 
correlates and were fully reversed at the end of the 2 -week recovery  period. Higher liver 
weights correlated with reversible, non-adverse microscopic findings of minimal to mild 
severit y in the liver and thyroid gland consistent with adaptive changes related to microsomal 
enzy me induction.
PF-07321332 was not  mutagenic or clastogenic in in vitro genetic toxicity  studies and was 
negative in the in vivo rat micronucleus assay  incorporated into the GLP repeat -dose rat 
toxicity  study . 
The nonclinical studies performed adequatel ysupport the ora l administration of 
PF-07321332 in the clinic for up to 14 day s.
Further details of the nonclinical safet y program are provided in the current IB.3
2.2.4. Clinical Overvie w
Safety , tolerability  and pharmacokinetics of PF -07321332 in 
healthy  adult participants is 
currentl y being explored in an ongoing Phase 1 FIH study (C4671001). Study  C4671001 is a 
4-part stud y consisting of SAD (PART -1), MAD (PART -2), relative bioavailability /food 
effect (PART -3) evaluations, and evaluation for m etabolism and excretion (PART -4). 
PART -1 and - 2 are randomized, double -blind, sponsor -open, and placebo -controlled to 
evaluate safet y, tolerability , and PK of single and multiple escalating oral doses of 
PF-07321332, respectively . PART -3 is randomized and open -label to evaluate relative 
bioavailability  and food effect of an oral tablet formulation. PART -4 is an open- label, 

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 18non-randomized, single period to evaluate the metabolism and excretion of PF-07321332.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 19 
 
 
2.3. Benefit/Risk Assessment
PF-07321332/ritonavir is not expected to provide any clinical benefit to healthy participants 
or participants with hepatic impairment in this study. This study is designed primarily to characterize the effect of hepatic impairment on the plasma PK of a single dose of PF-07321332 pharmacokinetically enhanced with ritonavir. The data from this study are expected to provide the basis for development of dosing recommendations for target patient populations who may have hepatic impairment. 
Based on preliminary data from the ongoing Phase 1 study (C4671001) collected as of 
07 April 2021 in PART-1 and 14 April 2021 in PART-2 (data snapshot taken), the clinical safety profile of PF-07321332 appears to be acceptable at single doses up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg at -12h, 0h, 12h), and at repeated daily doses administered orally for 10 days of up to 500 mg PF-07321332 BID with 100 mg ritonavir BID. 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-07321332 with ritonavir may be found in the IB and ritonavirUSPI
4, which are the SRSDs for this study.CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 20 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 21 
  
  
 
 
  
  
 
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 222.3.2. Benefit Assessment
PF-07321332/ritonavir will not provide any clinical benefit to healthy participants or 
participants with hepatic impairment in this study. Any anticipated benefit to participants would be in terms of contribution to the process of developing a new therapy in an area of unmet medical need.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures to minimize risk to study participants, the potential risks 
identified in association with PF-07321332/ritonavir are justified by the anticipated benefits that may be afforded to participants with COVID-19.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary:
•To compare the PK of PF-07321332, following 
a single oral dose administration of 
PF-07321332 pharmacokinetically boosted with ritonavir in adult participants with moderate hepatic impairment and age and body weight-matched participants without hepatic impairment.•Plasma PF-07321332 PK parameters: C
max, 
AUC last, AUC inf (if data permit)
Secondary: Secondary: 
•To evaluate the safety and tolerability of 
PF-07321332 and ritonavir, following a single oral dose administration of PF-07321332 pharmacokinetically boosted with ritonavir, in participants with moderate hepatic impairment 
and in healthy participants with normal hepatic 
function.•Incidence of TEAEs, abnormal ECGs, vital signs, and laboratory values
 
 
 
 
 
 
 
 
  
 
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 234. STUDY DESIGN
4.1. Overall DesignThis is a Phase 1, non-randomized, open-label, single-dose study to compare the 
pharmacokinetics of PF-07321332, given in combination with PK boosting agent, ritonavir, in adult participants with moderate hepatic impairment relative to participants without hepatic impairment. 
The study will have 2 cohorts: participants without hepatic impairment (Cohort 1) and 
participants with moderate hepatic impairment (Cohort 2).
Enrollment will be in a staged manner such that participants with hepatic impairment 
(Cohorts 2) will be enrolled first. Participants without hepatic impairment (Cohort 1) will begin recruitment towards the end of Cohort 2 or earlier, at the sponsor’s discretion, such that the enrollment in both cohorts may overlap. Participants in Cohort 1 will match the averagedemographics (at a minimum, age and weight; and gender as much as practically possible) of participants in Cohort 2. Approval from the sponsor must be obtained before proceeding with recruitment for participants in Cohort 1.
Table 1. Hepatic Function Categories Based on Child-Pugh Score
Cohort Description Child-Pugh Score Number of Participants
1 Without hepatic impairment Not Applicable 8
2 Moderate hepatic impairment Class B (7 to 9 points) 8
The Child-Pugh classification (CPC; Appendix 9 ) will be used to define the participants of 
Cohort 2 with moderate hepatic impairment (Child-Pugh Class B). 
All participants will be required to provide their own consent to participate in this study, 
hence participants with clinically active Grade 3 or Grade 4 encephalopathy will be excluded. However, participants who have a previous history of Grade 3 or Grade 4 encephalopathy but are currently receiving an intervention [for example: lactulose or lactitol, alone or in combination with rifaximin, and/or neomycin] to control their encephalopathy related signs and symptoms are eligible provided the on-treatment encephalopathy grading at the Screening visit is Grade 2 or lower thereby permitting them to provide their own informed consent. 
Eligible participants will be admitted to the CRU on Day -1 (at least 12 hours prior to the 
dosing of PF-07321332 on Day 1) and will be confined in the CRU until Day 3. On the evening of Day -1, participants will receive a single 100 mg dose of ritonavir (-12 hour relative to PF-07321332 dosing). On the morning of Day 1, the participants will receive a single dose of 100 mg PF-07321332 with a 100 mg dose of ritonavir after an overnight (or a minimum 6 hour) fast. Ritonavir, 100 mg, will continue to be dosed at 12 and 24 hours post PF-07321332 dosing to ensure maintenance of the PK boosting effect. Serial blood  samples at specified intervals will be collected for PK assessments as per SoA. Safety assessments will be performed during Screening, on Day -1 prior to dosing, and on Day 3. 
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 24Physical examinations and clinical laboratory tests will be conduc ted, and AEs will be 
monitored to assess safety. Vital signs and ECG measurements will be done on Day  1, prior 
to dosing. The total participation time (eg, CRU confinement time for study  procedures) for 
each participant in this study  is approximately  3nights/4 days (excluding S creening & 
Follow -Up contact). 
A safet y follow- up call will be made to participants 28 to 35 days from administration of the 
dose of study  intervention .
Participants who prematurely discontinue for non- safet y related reasons may be replaced, at 
the discretion of the PIand sponsor study  team.
The overall study design is summarized in Figure 1. For individual participants, the total
duration of participation from the Screening visit to the F ollow -Up visit will range from
5 weeks (minimum) to 9 weeks (maximum).
4.2.Scientific Rationale for Study Design
This study is a Phase 1, non-randomized, open -label study  of PF-07321332 in participants
with moderate hepatic impairment and participants with normal hepatic function , matched for 
age, bod y weight and, to the extent possible, for gender composition . Details on age and 
body  weight matching criteria are specified in Section 5.1. 
PF-07321332 alone is primarily  eliminated through a CYP450 mediated oxidation with 
CYP3A4 as the major contributor (f m= 0.99). However, in the presence of the CYP3A4 
inhibitor ritonavir, preliminary  data suggests renal excretion may  play  a significant role in 
PF-
07321332 excretion. In FIH stud y, approximately  64.6 % to 32.5% of the administered 
dose was excreted unchanged in urin eand remaining drug may  get eliminated via 
metabolism .Preliminary  PBPK modeling suggests < 2 × increase in AUC in mild hepatic 
impaired participants (Child -Pugh A) and < 3 × increase in moderate (Child -Pugh B) hepatic 
impaired participants. There fore, the PK will only  be evaluated in moderately  hepatic 
impaired participants. Ritonavir has not been studied in severe hepatic impaired patients and 
currentl y prohibited to be used in those population. Therefore, this study does not plan to 
evaluate 
PK in severel y hepaticall y impaired participants.
A single dose of PF -07321332 was selected and is considered appropriate as available data 
do not indicate PF- 07321332 PK are time -dependent, and hence, single dose data are 
considered predictive of steady state. As ritonavir is not eliminated renally , multiple doses of 
100mg ritonavir will be administered at -12, 0, 12, and 24 hours relative to PF -
07321332 
dosing to ensure adequate PK boosting effect over the duration of PF -07321332 exposure. 
PF-07321332 is not extensively  bound to human plasma proteins, with f uof 0.31 observed in 
the in vitro protein binding study. Thus, no additional blood samples will be collected in this 
study  for ex vivo protein binding anal ysis.

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 254.2.1. Choice of Contraception/Barrier Requirements
Human reproductive safety data are limited for PF-07321332, but there is no suspicion of 
human teratogenicity based on the intended pharmacology of the compound. Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
 
4.3. Justification for Dose
A single oral dose of 100 mg PF-07321332, pharmacokinetically enhanced with ritonavir 
(100 mg at -12, 0, 12, and 24 hours relative to PF-07321332), is planned in this study. This is anticipated to be at the lower end of the clinically effective dose range, and below theanticipated Phase 2/3 dose of PF-07321332/ritonavir of 300/100 mg. Although single doses up to 750 mg PF-07321332 with ritonavir have been evaluated, exposure increased less than dose proportional within the 250 mg to 750 mg dose range evaluated. Therefore, 100 mg PF-07321332 is appropriate considering systemic exposures of PF-07321332 may be increased when administered in hepatic impairment.
When co-administered with ritonavir, doses of PF-07321332 up to 750 mg single dose and 
500 mg q12h for 10 days were generally safe and well tolerated based on preliminary data from the Phase 1 Study C4671001. There have been no deaths or serious adverse events or SUSARs reported. Based on review of preliminary (unaudited) data, all reported adverse events have been of mild intensity. There were no clinically meaningful findings in vital signs, ECG, or potential Hy’s Law cases reported during the study. 
Using preliminary PBPK model, the projected AUC and C
maxat the proposed dose are
 which are below the highest observed exposures at safe and 
tolerate dose in study C4671001 and are approximately 19 × and 25 × below NOAEL exposures observed in toxicity st udies in rats, respectively.
The dose of ritonavir to be used in this study is 100 mg administered BID. This dose is the 
typical dose of ritonavir when dosed as PK enhancer.
4.4. End of Study Definition
The end of the study is defined as the date of the last visit of the last participant in the study.
A participant is considered to have completed the study if he/she has completed all phases of 
the study, including the last visit. 
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should beCCI
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 26taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1. Inclusion Criteria
Participants are eligible to be in cluded in the study onl y if all of the following criteria appl y:
Age and Sex :
1. Participants must be 18 to 75 years of age, inclusive, at the time of signing the I CD.
[For Cohort 1 only] Each participant’s age iswithin ±10 y ears of the mean age of 
the 
hepatic impairment group. Attempts will be made to ensure that the male -to-
female distribution in Cohort 1 is comparable to that in hepatic impairment
cohort, Cohort 2.
Refer to Appendix 4forreproductive criteria for male (Section 10.4.1 )and female
(Section 10.4.2) participant s.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
3.
[For Cohort 1 only] Male and female participants who are classicall y healthy having 
no clinically  relevant abnormalities as determined by  medical evaluation including 
medical history , phy sical examination including blood pressure a nd pulse rate 
measurement, 12 -lead ECG, and laboratory  tests. No known or suspected hepatic 
impairment. 
4. [for Cohort 2 only] Stable hepatic impairment that meets the criteria for Class B of 
the CPC (refer to Appendix 9) with no clinically  significant change in disease status 
within the 28 day
s prior to the Screening visit, as documented by the participant’s 
recent medical history  (for example: no worsening clinical signs of hepatic 
impairment, no worsening of total bilirubin or PT by  more than 50%).
Weight:
5.BMI of 17.5 to 40kg/m2; and a total bod y weight >50 kg (110 lb).
[For Cohort 1only] Each participant’s bod y weight within ±15 kg of the mean 
body  weight of hepatic impairment group .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 27Informed Consent:
6.Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
2.Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, ileal resection ) .
NOTE : Participants who have undergone cholecy stectomy  and/or appendectomy  are
eligible for this study  so long as the surgery  occurred more than 6 months prior to 
Screening.
3. At screening, participants with a positive result for HIVantibodies. 
4. [For Cohort 1 only ] Participants with chronic live r disease including history  of 
hepatitis, hepatitis B, or hepatitis C or evidence of active disease , at screening.
NOTE: P articipants with a previousl y positive hepatitis B surface antibod y result due 
to vaccination are deemed eligible.
5. [For Cohort 2 only] 
Hepatic carcinoma orhepatorenal s yndrome orlimited predicted life expectancy  
(defined as less than 1year).
A diagnosis of hepatic d ysfunction secondary  to any  acute ongoing hepatocellular 
process that is documented by  medical history , phy sical examin ation, liver 
biopsy , hepatic ultrasound, computerized tomography  scan, or MRI.
Signs of clinicall y active Grade 3 or Grade 4 hepatic encephalopathy  
(ie,>Grade 2 Portal S ystemic Encephalopath y score; refer to Appendix 9).
Severe ascites and/or pleural effusion.
History  of kidney , liver, or heart transplantation.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 286.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other co nditions or 
situations related to COVID -19 pandemic (eg ,Contact with positive case, residence, 
or travel to an area with high incidence) that may  increase the risk 
ofstudy 
participation or , in the investigator’s judgment, make the participant inappropria te for 
thestudy .
Prior/Concomitant Therapy:
7.
Participants who have been vaccinated with COVID- 19 vaccines within the past 
1week of dosing.
8.Previous administration with an investigational drug within 30days(or as determined 
by the local requirement) or 5 half-lives preceding the first dose of investigational 
product used in this study  (whichever is longer) .
9.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention ( Refer to Section 6.8 Concomitant Therap y for additional details ).
Limited use of nonprescription medications that are not believed to affe ct participant 
safet y or the overall results of the study may be permitted on a case -by-case basis 
following approval b y the sponsor. 
For participants with hepatic impairment, stable concomitant medications (including 
herbal supplements) may be given following approval by the sponsor if they are 
considered necessary  for the welfare of the study  participants (eg, standard therapy  
for underl ying diseases), are not contraindicated with the IP, and are unlikely  to 
interfere with the PK of the I P.
10.Current use of any  prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s) (Refer to Section 6.8 Concomitant 
Therap y for additional details ).
Prior/Concurrent Clinical Study Experience:
11.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study  intervention
used in this study  (whichever is longer) .
12. Participants with known prior participation (ie, randomized and received at least 
1dose of investigational product) in a stud y involving PF -07321332.
Diagnostic Assessments:
13.A positive urine drug test at Screening or on Day  -1.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 29NOTE: Participants in Cohort 2 who have been medica lly prescribed opiates/opioids 
or benzodiazepines and report the use of these drugs to the investigator at Screening 
may be allowed to participate if approved by  the sponsor .
14.In females of childbearing potential, a positive urine pregnancy  test at Screening or 
Day -1.
15.
Vital sign measurements at Screening that demonstrates:
[For Cohort 1 only ] Screening seated BP ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), following at least 5 minutes of rest. 
[For Cohort 2 only ] 
Screening 
seated BP ≥180 mmHg and/or ≥100mmHg (diastolic) following at 
least 5 minutes of rest.
NOTE : If S
BP is ≥140 mmHg (for Cohort 1) or≥180mmHg (for Cohort 2) orif 
DBP ≥90mmHg (for Cohort 1) or ≥100mmHg(for Cohort 2), the BP should be 
repeated 2 more times and the average of the 3 BP values should be used to 
determine the participant ’s eligibility .
For participants with SBP ≥160 (and <1 80) mm Hg orDBP ≥ 95(and 
<100)mmHg, the period between Screening and Day  -1 must be used to refine 
the doses of the agents used for management of BPwith the aim to have stable BP 
byDay -1. Participants must have measurement on Day 1 of SBP ≤ 160mmHg 
andDBP <
95mm Hg .
16.Screening standard 12- lead ECG thatdemonstrates :
Clinica llyrelevant abnormalities requiring treatment (eg , acute my ocardial 
infarction, serious tachy -or brad y
-arrhythmias) or indicating serious underly ing 
heart disease (eg, prolonged PR interval, cardiomy opathy , underl ying structural 
heart disease, Wolff Park inson- White sy ndrome ); 
[For Cohort 1 only ] Screening supine 12-lead ECG demonstrating QTcF interval 
>450 msec or a QRS interval >120 msec ;
[For Cohort 2 only ] Screening supine 12-lead ECG d emonstrating a QTcF 
interval >470 msec or a QRS interval >120 msec ;
NOTE : If QTcF exceeds 450 msec (for Cohort 1) or 480 msec (for Cohort 2) , or
QRS exceeds 120 msec, the ECG should be repeated 2 more times and the 
average of the 3 QTcF or QRS values should be used to determine eligibility .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 3017.Participant s with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed by  a single 
repeat test, if deemed necessary :
eGFR <60 mL/min/1.73m2based on the CKD -EPI equation , with single repeat
allowed.
[For Cohort 1 only ]
AST 
orALT level ≥ULN ;
Albumin > ULN;
Prothrombin time > UL N;
Total bilirubin level ≥1.5 × ULN;
NOTE: 
Participants with a history of Gilbert s yndrome (and hence elevated 
total bilirubin) are eligible provided direct bilirubin level is ≤ ULN;
[For Cohort 2 only] ALT orAST >5 × ULN
18.In the opinion of the investigator or Pfizer (or designee), have an y clinically 
significant laboratory  abnormality  that that could affect interpretation of study  data or 
the participant’s participation in the study .
Other Exclusions:
19.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drink s in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
At Screening or Day  -1, a positive breath alcohol test or urine test .
20.Female 
participants of childbearing potential who are unwilling or unable to use 
highl y effective methods of contraception as outlined in Section 5.3.4 for the duration 
of the study  and for at least 28 day s after the administration of investigational 
product , pregnant female participants, female participants planning to become 
pregnant during the duration of the study  until 28 day s after the administrati on of 
investigational product, breastfeeding female participants.
21.Blood donation (excluding plasma donations) of approximately  1pint (500 mL)or 
more within 60days prior to dosing .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 3122.History  of sensitivity  reactions to ritonavir, or any of the formulation components of 
PF-07321332 or ritonavir.
23.History  of sensitivity  to heparin or heparin induced thrombocy topenia , only  if heparin 
is used to flush intravenous catheters used during serial blood collections .
24.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol
.
25.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respective family  
members .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and overnight (at least 6 hours) prior to the 
collection of the predose PK sample and PF- 07321332 administration on Day  1.
There will be no restriction to breakfast on the other day s provided other restrictions 
are followed.
Water is permitted until 1 hour prior to 
study  intervention administration. Water may  
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit related citrus fruit juices - see below ) may  be 
consumed with meals and the evening snack .
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos) from 7 days prior to the first dose of 
study  
intervention until collection of the final PK blood sample.
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed appro ximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Consumption of caffeinated drinks and tobacco (or 
nicotine containing products) is 
permitted during participation in the study ; however, there may  be a need for brief 
interruption while at the site, depend ing on local site policy .
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace w ill be permitted .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 32In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP,pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during t he first 
4 hours after dosing of PF -07321332 (does not apply  to ritonavir dosing ).
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Sec tion 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities ( SoA), the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctl y and document the conversation and the participant ’s 
affirmation in the participan t’s chart ( participant s need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy  may  have changed since the last visit . In addition, the investigator or designee will 
instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported to the clinical database.
Individuals w ho do not meet the criteria for participation in this study  (screen failure) may be 
rescreened if prior reason for not meeting the eligibility  criteria has been resolved. 
Rescreening may  onl
y occur with sponsor approval. In the event that the participation of a 
participant in the study  is delay ed, outdated screening procedures can be repeated. 
Rescreened participants should be assigned the same participant number as for the initial 
screening .
6.STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07321332 and ritonavir. 
6.1.Study Intervention(s) Administered
For this study , the investigational products are PF -07321332 (provided as 100 mg tablets) 
and ritonavir (provided as 100 mg tablets).
PF-07321332 100 mg tablets and ritonavir 100 mg tablets will be supplied by  Pfizer to the 
CRU in bulk along with individual dosing containers for unit dosing.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 336.1.1. Administration
Investigational products will be administered orally  and according to the conditions 
described in the SoA section and Protocol Section 5.3.1 Meals and Dietary  Restrictions.
On Day  -1, 12 hours prior to dosing of PF-07321332, participants will receive a 100 mg 
ritonavir tablet (as 1 × 100
mg) with approximately  240 mL ambient temperature water. On 
Day 1, following an overnight fast of at least 6hours, participants will receive 100 mg 
PF-07321332 (as 1 × 100 mg tablet) at approximately  0800 hours ( plus or minus 2 hours) 
and 100 mg ritonavi
r (as 1 × 100 mg tablet). Participants will receive 2 additional doses of 
100 mg ritonavir (as 1 × 100 mg tablet) at 12 and 24 hours after receiving PF-07321332. 
Investigator site personnel will administer study  intervention with ambient temperature water 
to a total volume of approximately  240 mL. Participants will swallow the study  intervention 
whole and will not manipulate or chew the stud y intervention prior to swallowing. 
In order to standardize the conditions of PK sampling, all participants will be r equired to 
refrain from l ying down (except when required for ECG measurements), eating, and drinking 
beverages other than water during the first 4 hours after dosing of PF- 07321332.
6.2.Preparation , Handling , Storage , and Accountability
1.The investigator or des
ignee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business
.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with any actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not u sed until Pfizer provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the IP manual. 
4.Any storage conditions s tated in the SRSD will be superseded b y the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 346.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible f or study  intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a stud y interven tion accountabilit y form/record.
7.Further guidance and information for the final disposition of unused study  
interventions are provided in the IP manual .All destruction must be adequately  
documented. If destruction is authorized to take place at the invest igator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon identification of a product complaint, notify th e sponsor w ithin 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  qualified staff member(s) to a healthcare provider, 
participant in accordance with this protoco l. Local health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
PF-07321332 and ritonavir tablets will be prepared at the CRU in the individual dosing 
containers b y 2operators, 1
of whom is an appropriately  qualified and experienced member 
of the study  staff (eg, phy sician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  
assistant/technician, or pharmacist). The tablets will be provided to the participant 
in unit 
dose containers an d labeled in accordance with Pfizer regulations and the clinical site’s 
labeling requirements . 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the de cision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . All participants enrolled will receive treatment according to the dose/schedule.
6.4.
Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose
administered i n the clinic will be recorded in the source documents and recorded in the CRF.
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administeri ng the 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 35study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Dose Modification
Dose modifications for PF -07321332 and ritonavir are not allowed. 
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 100 mg or ritonavir greater than 
200mg within a 24-hour time period will be considered an overdose.
There is no specific treatment for an overdose .
In the event of an overdose, the investigator should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -07321332 or ritonavir 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportabl e to Pfizer Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 2days from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case -by-case 
basis).
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed t o affect 
participant safety  or the overall results of the study may
 be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
As PF -07321332 and ritonavir are both primaril y metabolized by  CYP3A4, concomitant use 
of an y medications or substances that are strong inducers of CYP3A4 are prohibited within 
28days prior to dosing of investigational product. Additionally , ritonavir and PF -07321332 

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 36are inhibitors of CYP3A4. Therefore, medications highly dependent on CYP3A4 for 
clearance and for which elevated plasma concentrations may be associated with serious and/or life-threatening events are not permitted during dosing of PF-07321332/ritonavir. A non-exhaustive list of prohibited and precautionary medications is provided in Appendix 8 . If 
a medication is not listed, it should not automatically be assumed it is safe to co-administer.
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. All participants will be questioned about concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study intervention will be 
documented as a prior treatment. Treatments taken after the first dose of study intervention will be documented as concomitant treatments.
6.8.1. Participants with Healthy Liver Function (Cohort 1)
In general, participants will abstain from all concomitant treatments (prescription or over the 
counter) as described in Section 6.8 , except for the treatment of AEs. Of note, the following 
restrictions apply:
•Limited use of nonprescription medications that are not believed to affect participant 
safety or the overall results of the study may be permitted on a case-by-case basis after approval by the sponsor.
6.8.2. Participants with Impaired Liver Function (Cohort 2) 
Participants are permitted to be on stable doses (at least up to 5 half-lives) of background 
medications if they are considered necessary for the welfare of the study participants (eg, standard therapy for the underlying disease), are not contraindicated with the investigational product, and are unlikely to interfere with the PK of the investigational product. Whenever 
possible , attempts must be made to notalter the doses and regimens of the concomitant 
medications after Day 1 and until the end of study on Day 3.
•Approved concomitant medications should be administered to hepatically impaired 
participants at least 2 hours prior to dosing or withheld until 4 hours after PF-07321332 dosing.
6.8.3. Rescue Medicine
There is no rescue therapy to reverse the AEs observed with PF-07321332 or ritonavir ˗
standard medical supportive care must be provided to manage the AEs. 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIt may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following.
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 37AEsrequiring discontinuation in investigator’s view;
Pregnancy ;
Positive COVI D-19 test.
Note that discontinuation of study  intervention does not represent withdrawal from the study .
If study  intervention is permanentl ydiscontinued, the participant will remain in the study  to 
be evaluated for safet y and PK, if possible . See the SoA for data to be collected at the time of 
discontinuation of study  intervention and follow -up for any  further evaluations that need to 
be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow - up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/ Withdrawal
From the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by  sponsor ;
At the 
time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow -upand for an y furt her evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
The participant will be permanentl y discontinued from the study intervention and the study  at 
that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested
,and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 38If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of C onsent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol specified follow - up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any  further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, when ever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow- up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordanc e with local law.
7.3.Lost to 
Followup 
A participant will be considered lost to - follow -upif he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for /attend a 
required stud y visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -
up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y -specific procedures.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 39Study  proced ures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evalu ations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
scree ning failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
Every  effort should be made to ensure that protocol required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator mus t take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiati on of the study .
The total blood sampling volume for individual participant s in this study  isapproximately  
90mL.The actual collection times of blood sampling may  change. Additional blood samples 
may be taken for safet y assessments at times specified by Pfizer, provided the total volume 
taken during the stud y does not exceed 550 mL during an y period of 
60consecutive day s.
To prepare for stud y participation, participant s will be instructed on the information in 
Section 5.3 LifestyleConsiderations andSection 6.8Concomitant Therap ysections of the 
protocol.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 408.1.Efficacy Assessments
Not Applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided i n the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a m inimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory  and cardiovascular s ystems, and 
participant reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. 
Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study will be consider ed source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to8.3.3.
8.2.2. Vital Signs
Seated BPwill be measured with the participant ’s arm supported at the level of the heart and 
recorded to the nearest mm Hgafter approximately  5minutes of rest . The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times
,of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 418.2.3. Electrocardiograms
Standard 12-l ead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supine position. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥30 msecfrom the baseline andis >450 msecfor 
participants with normal hepatic 
function and >470 msec for participants with impaired 
hepatic function; or b) an absolute QT value is ≥ 500msecfor any  scheduled ECG. If either 
of these conditions occurs, then 2 additional ECGs will be collected approximately  2to 
4 minutes apart to confirm the original measurement. If the QTc values from these repeated 
ECGs remain above the threshold value, then a single ECG must be repeated at least hourl y 
until QTc values from 2 successive ECGs fall below the threshold value that triggered the 
repeat measurement.
If a) a postdose QTc Finterval remains ≥30msecfrom the baseline andis >450 msecfor 
participants with normal hepatic function and >470 msec for participants with impaired 
hepatic function; or b) an absolute QT value is ≥500msecfor any  scheduled ECG for greater 
than 4 hours (or sooner, at the discretion of the investigator); or c) QTcFintervals get 
progressivel y longer, the participant should undergo continuous ECG monitoring. 
A cardiologist shoul d be consulted if QTc F intervals do not return to less than the criteri a
listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted inAppendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the S
oAfor 
the timing and frequency. All protocol required laboratory  assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 42The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28 calendar days after the last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no long er considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
If laboratory  values from non- protocol specified laboratory  assessments performed at the 
institution’s local l aboratory require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
Participant s may  undergo random urine drug testing at the discretion of the investigator.
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.5. COVID -19 specific assessments
Participants will be tested for SARS -CoV -2 infection as per site -specific regulations prior to 
being admitted to the clinic for confinement and a subsequent COVID -19 test will be 
performed if they  develop COVID
-19 like s ymptoms. Additional testing may  be required by  
local regulations or b y the Principal Investigator.
8.2.6. Pregnancy Testing
Pregn ancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .
Following a negative pregnancy  test result at screening, appropriat e contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs/ ECs or if required by local regulations. If a urine test cannot 
be confirmed as negative ( eg, an ambiguous result), a serum pregnancy  test is required. In 
such cases, the participant must be excluded if the serum pregnancy  result is positive .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 438.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authoriz ed representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to ass ess whether 
the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy (see Section 7.1 ). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -up
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study  related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar days ,after the last administration of the study  intervention .
Follow -upby the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study because of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT 
SAE Report Form.
Investigators are not obligate d to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 448.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during t he active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety on the CT SAE Report Form imme diately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Record ing Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
Reporting of AEs and SA Es for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand th
e 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the partic ipant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -upof AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to - follow -up(as defined in Section 7.3).
In general, follow -upinformation will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -upprocedures is given in Appendix 3.
8.3.4. Regulatory 
Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 45The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country  specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include ex posure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such e xposure to the study  intervention under study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if : 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by ingestion .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  ingestion then exposes his female partner prior to or around the 
time of conception .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 46should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregn ancy  will be collected after the start of study  intervention and until 28 day s after 
the last dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Suppl emental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -upis conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome a sa 
follow -upto the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinical ly possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considere d SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonata l deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
expo sure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Further follow -
upof birth outcomes will be handled on a case -by-case basis (eg, follow -upon preterm 
infants to identify  developmental delay s). In the case of paternal exposure, the investigator 
will provide the participant with the Pregnant Partner Release of Information Form to deliver 
to his partner. The investigator must document in the source documents that the participant 
was given the Pregnant Partner Release of Information Form to provide to his partner.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 478.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female fami ly member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
byingestion .
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awar eness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the particip ant enrolled in the stud y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational E xposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 24 
hours of the investigator’s awareness 
using the CT SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occup ational exposure does not 
pertain to a participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease Related Events and/or Disease Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applicable.

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 488.3.8.1. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study intervention under study may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
•Medication errors involving participant exposure to the study intervention;
•Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
8.4.1. Plasma for Analysis of PF-07321332Blood samples of approximately 4 mL, to provide a minimum of 1.5 mL plasma, will be
collected for measurement of concentrations of PF-07321332  as specified in the 
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 49SoA . Instructions for the collection and handling of biological samples will be provided in 
the laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the data collection tool (eg, CRF/DCT). Collection of samples more than 10 hours after dose administration that are obtained ≤1 hour away from the nominal 
time relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the data collection tool (eg, CRF/DCT). This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples will be used to evaluate the PK of PF-07321332 . Each plasma sample 
will be divided into 2 aliquots. Samples collected for analyses of PF-07321332  plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, .
Genetic analyses will not be performed on these plasma samples. Participant confidentiality 
will be maintained.
Samples collected for measurement of plasma concentrations of PF-07321332  
will be analyzed using a validated analytical method in compliance with applicable SOPs.Potential metabolites may be analyzed with either validated or exploratory methods.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor.On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
 
 
 
 CCI
CCI
CCI
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 50 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 518.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; ho wever, an y major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
No statistical hy pothesis will be tested in this study.
9.2.Analysis Sets
For purposes of analy sis, the following 
analysis sets are defined:
Participant Analysis 
SetDescription
PK Concentration The PK concentration population is defined as all participants 
assigned to investigational product and treated who have at 
least 1 concentration measured.
PK Parameter The PK parameter anal ysis population is defined as all 
participants assigned to investigational product and treated 
who have at least 1 of the PK parameters of primary interest 
measured.
Safety  Anal ysis Set All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention. Participants 
will be anal yzed according to the product they  actually  
received.
9.3. Statistical Analyses
The SAP will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
One-way ANOVA will be used to compare the natural log transform
ed AUC last, AUC inf(if 
data permit) and C maxfor PF -07321332 between Cohort 2 with moderate hepatic impairment 

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 52(Test) and Cohort 1 with normal hepatic function (Reference). Estimates of the adjusted 
mean differences (Test-Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean differences and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of the adjusted geometric means (Test/Reference) and 90% CIs for the ratios. 
Box and whisker plots for individual participant parameters (AUC
infand C max) will be
constructed by cohort and overlaid with geometric means.
For summary statistics and median/mean plots by sampling time, the nominal PK sampling 
time will be used. For individual participant plots by time, the actual PK sampling time will be used.
9.3.1. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, and safety laboratory data will be reviewed and summarized on an ongoing basis during 
the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE.Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
 
9.3.2.1. Pharmacokinetic Analyses
9.3.2.1.1. Analysis Population
The PK concentration population will be defined as all participants treated in whom at least 
1 plasma concentration value is reported.
The PK parameter analysis population is defined as all participants dosed who have at least 
1 of the PK parameters of primary interest.CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 539.3.2.1.2. Derivation of Pharmacokinetic Parameters Prior to Analysis
The plasma PK parameters for PF-07321332 will be derived from the concentration time 
profiles as detailed in Table 2. Actual PK sampling times will be used in the derivation of PK parameters. In the case that actual PK sampling times are not available, nominal PK sampling time will be used in the derivation of PK parameters.
Table 2. Plasma PK Parameters
Parameter Analyte Definition Method of Determination
AUC last PF-07321332 Area under the plasma 
concentration-time profile from 
time 0 to the time of C lastLinear/Log trapezoidal method.
 
AUC inf*PF-07321332 Area under the plasma 
concentration-time profile from time 0 extrapolated to infinite 
timeAUC
last+ (C last*/kel), Where C last*is 
the predicted plasma concentration at the last quantifiable time point 
estimated from the log-linear 
regression analysis.
Cmax PF-07321332, ritonavirMaximum plasma concentration Observed directly from data.
  
 
 
 
 
* As data permit.
 
  
  
 CCI
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 549.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label study, 
the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical development. 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 5510. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines ,
including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicabl e laws and regulations, including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor ,submitted to an I RB/EC 
by the investigator, and revi ewed and approved by  the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by  
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medi cal Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immedia tely.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 56In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guide lines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent P rocess
The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participant and answer all questions regarding the study . The 
participant should be given sufficient time and opportunity  to as k questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing o f data related to the study , and possible risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other auth orized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which 
the writ ten consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 57A cop y of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password- protected to ensure that only authorized study  staff have access. The study  
site will implement appropriate technical and o rganizational measures to ensure that the 
personal data can be recovered in the event of disaster. In the event of a potential personal 
data breach, the stud y site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications as required by law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant specific numerical code. Any  
participant recor ds or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the con fidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
This study  will not use a DMC.
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 58regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT
Pfizer posts clinic al trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this po licy,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participan tdata. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provi ded to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 59Guidance on completion of CRFs wil l be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password -protected to prevent access by  unauthorized third parties.
The investi gator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processe s(eg, risk-based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities
,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part ywithout written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are iden tified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 60Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous m
edical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the clinical 
monitoring plan ,which is maintained by  the sponsor .
Descrip tion ofthe use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by  the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clini cal study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study at an y 
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a study -siteclosure visit has bee n performed.
The investigator may  initiate study -siteclosure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 61Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the re gulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol
,the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study may be published or presented at scientific meetings b y the
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention
related information necessary  for the appropriate scientific presentation or understanding of
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their 
entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Commi ttee of Medical Journal Editors authorship 
requirements. 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 62If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact information for the spon sor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the SToD system . 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participan ts are provided with an Emergency  Contact Card (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) Pfizer Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professionals not involved in the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Center number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 6310.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory, or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 4. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils 
(Abs)Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea and creatinine
GlucoseCalcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Alkaline phosphatase
Total bilirubinDirect bilirubin
a
Indirect bilirubina
Uric acidAlbumin
Total proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitritesLeukocyte esterase
Urobilinogen
Urine bilirubin
Laboratory:
Microscopyb•SARS-CoV-2 RT-PCRc
•Urine drug screeningd
•Breath or urine alcohol 
teste
•Pregnancy test ( β-hCG)f
At Screening Onlyg:
•PT
•aPTT
•PT-INR
•HIV
•HbsAg
•HbcAbh
•HCVAbi
•FSHj
a. Direct and indirect bilirubin assessed when total bilirubin is > ULN, only.
b. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
c. Testing for COVID-19 pathogen will be performed prior to being admitted to the clinic for confinement, on 
Day -1, and if participant develops COVID-19 like symptoms.
d. At Screening and Day -1; The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, 
benzodiazepines, and amphetamines (others are site and study specific).
e. At Screening and Day -1.
f. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or 
IRB/EC. Serum or urine β-hCG for female participants of childbearing potential. 
g. Tests will only be performed at Screening. h. HBsAb will be performed as reflex testing for any participant who is HBsAg negative and HBcAb positive.
i. HCV RNA will be performed as reflex testing for any participant who is HCV Ab positive.
j. At Screening for confirmation of postmenopausal status only.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
Samples to be used for this 
purpose will be shipped to either a Pfizer-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 6410.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or di sease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after study intervention administration,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either st udy 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 65Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing ho spitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs . 
If a complication prolongs hospitalization or fulfills any  other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 66d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious.
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases by 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by the investigator in 
deciding whether SAE reporting is appropriate in other situations ,such as 
significant medical events that may  jeopardize the participant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do n ot result in hospitalization, or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonse rious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 67It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB).None. Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whethe r or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE 
Report Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also include 
details of any SAE that mig ht be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational 
exposure are reported to Pfizer Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 68It is notacceptable for the investiga tor to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In thi s case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs,
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious
”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
If required on the AE page of the CRF, the investigator will use the adjectiv es 
MILD, MODERATE, SEVERE, or VERY SEVERE to describe the maximum 
intensity  of the AE. The severit y of the AE should be determined using the Toxicity  
Grading Scale: 
MILD Does not interfere with participant 's usual function.
MODERATE Interferes to some extent with participant 's usual function.
SEVERE Interferes significantl y with participant 's usual function.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 69VERY SEVERE Unacceptable and intolerable events or events which are 
irreversible or cause the participant to be in imminent danger of 
death.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled o ut.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also cons ult the IB and/or product information, for 
marketed products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be si tuations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initia l transmission of the SAE data to the 
sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteri a used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, as defined by  thesponsor . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT S AE Report Form and in 
accordance with the SAE reporting requirements.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 70Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with oth er 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings
,including histopathology .
New or updated informati on will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool 
will be taken off -line to preve nt the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection 
tool has been taken off -line, then the site c an report this information on a paper 
SAE form (see next section) or to Pfizer Safet y by telephone.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 71SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 7210.4. Appendix 4:Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lif estyle (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may  
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), as described below during the intervention period and for at 
least 28 day safter the last dose of PF-07321332, which corresponds to the time 
needed to eliminate an y reproductive safet y risk of the study intervention. If a highl y 
effective method that is user dependent is chosen, a second effective method of 
contraception, as described below (except options 5 and 6)
, must also be used . The 
investigator should evaluate the ef fectiveness of the contraceptive method in 
relationship to the first dose of study  intervention.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 73The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented hy sterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretio n 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contracep tion methods if they  
wish to continue their HRT during the stud y.Otherwise, they  must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 7410.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing system .
4.Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole s exual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
6.Combined (estrogen- and progestogen -containing ) hormonal contraception 
associated with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal .
7.Progestogen -only hormone contraception associated with inhibition of ovulation .
Oral;
Injectable .
8.Sexual absti nence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the study  and the preferred and usual 
lifesty le of the participant.

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 75One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide ;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 76 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 7710.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.
Participant s who experience a transaminase elevation above 3 ×ULN sho uld be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pically  occurs whil e AST/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by the time TBili elevations are detected, 
AST/AL T values might have decreased. This occurrence is still reg arded as a potential DILI.
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who prese nt 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal ra nge who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili se parated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 78The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements o f AST and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalitie s to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplem ent 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be coll ected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s
for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat t esting as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be repo rted as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations hav e been received and have excluded an alternative etiology .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 7910.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -onset typeI second -degree (Wenckebach) AV block of >30 seconds’
duration
.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset left bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, sy mptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, sy mptom -free participant s with atrial fibrillation and brad ycardia 
with 1 or more pauses of at least 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response r ate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 80Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete ( third
-degree ) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third- degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SA Es.

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 81 
 
 
 
 
 
 
 
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 82 
 
  
 
 
  
 
 
 
 
 
 
 
 
   
  
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 83   
 
 
  
 
 
 
   
 
  
 
 
 
 
 
 
 
.CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 8410.9. Appendix 9: Child -Pugh Classification (CPC) of Liver Dysfunction 
Table 5. Scoring for Child -Pugh Classification
Cohort CPC Level of dysfunction Total Score 
(tally based on assessment of 
param eters in Table 6
)
1 Not Applicable Without hepatic impairment Not Applicable
NA A Mild 5-6
2 B Moderate 7-9
NA C Severe ≥10
Table 6.Derivation of Child -Pugh Classification Score
Assessment 
Param etersAssigned score for observed findings
1 point 2 points 3 points
Encephalopathy gradea
(refer to Table 7below )0 1 or 2 3 or 4a
Ascites Absent Asymptomatic Requiring intervention
Serum total bilirubin, 
mg/dL<2 2 to 3 >3
Serum albumin, g/dL >3.5 2.8 to 3.5 <2.8
Prothrombin time, sec 
prolongedb<4 4 to 6 >6
a. Participants with a prior history of Grade 3 or Grade 4 encephalopathy who are currently receiving 
anintervention [for example : lactulose or lactitol, alone or in combination with rifaximin, and/or neomycin] to 
manage encephalopat hy-related signs and symptoms should be scored for encephalopathy grading based on their 
presentation while on intervention at the Screening visit and can be included in this study as long as they do not
have clinically active Grade 3 or Grade 4 encephalopathy.
b. As assessed relative to PT control ( orupper limit of normal) .
Table 7. Determination of Encephalopathy Grade
Encephalopathy Grade Definition
0 Normal consciousness, personality, neurological exam
1 Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting
2 Lethargic, time disoriented, inappropriate, asterixis, ataxia
3aSomnolent, stuporous, place disoriented, hyperactive reflexes, rigidity
4aUnrousable coma, no personality/behavior, decerebrate
a. Participant s with clinically active Grade 3 or 4 encephalopathy are excluded.
CPC should be assessed at Screening to determine the classification of a given 
participant.

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 8510.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
→ ongoing/continuous event
3CLpro3C-like protein
Ab antibody
Abs absolute
ADL activities of dail y livin g
AE adverse event
 
 
ALT alanine aminotransferase
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the curve
 
 
AUC inf area under the plasma concentration-time profile from time 0 
extrapolated to infinite time
AUC last area under the plasma concentration-time profile from time 0 to the time of C
last
AV atrioventricular
β-hCG beta-human chorionic gonadotropin
BBS Biospecimen Banking System
BID twice a day
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney disease
CKD -EPI Chronic Kidney Disease -Epidemiology Collaboration
Clast predicted plasma concentration at the last quantifiable time pointCCI
CCI
CCI
CCI
PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 86Abbreviation Term
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID-19 coronavirus disease 2019
CPC Child-Pugh score
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study Report
CT clinical trial
CYP cytochrome P450 
CYP3A4 cytochrome P450 3A4 
DBP diastolic blood pressure
DC discontinuation
DCT data collection tool
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
EC ethics committee
ECC Emergency Contact Card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during breastfeeding
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FIH first-in-human
fm fraction metabolized
FSH follicle stimulating hormone
fu fraction unbound
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GLP Good Laboratory Practice
H hour
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCoV-OC43 human coronavirus OC43
HCoV-229E human coronavirus 229ECCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 87Abbreviation Term
HCoV -HKU1 human coronavirus HKU1
HCoV -NL63 human coronavirus NL63
HCVAb hepatitis C antibody
HCV hepatitis C virus
hep C hepatitis C
HI hepatic impairment 
HIV human immunodeficiency virus
HMG CoA reductase 3-hydroxy -3-methy l-glutary l-CoA reductase
HR heart rate
HRT hormone replacement therap y
IB Investigator's Brochure
ICD informed consent document
ICH International Council for Harmonisation
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB Institutional Review Board
IV intravenous
kel elimination rate constant
Ki inhibition constant
LFT liver function test
MAD multiple ascending dose
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MERS Middle East respiratory  syndrome 
MRI magnetic resonance imaging
N/A not applicable
NHP non-human primate
NNRT non-nucleoside reverse transcriptase
NOAEL noobserved adverse effect level
NTI narrow therapeutic index
PAH pulmonary  arterial hy pertension
PBPK physiologicall y based pharmacokinetic
PD pharmacod ynamic(s)
PE physical examination
pH potential of hy drogen
PI principle investigator
PK pharmacokinetic(s)
PR pulse rate

PF-07321332 
Protocol C4671010Final Protocol, 25 June 2021
PFIZER CONFIDENTIAL
Page 88Abbreviation Term
PT prothrombin time
PT-INR prothrombin time-international normalized ratio
PVC premature ventricular contraction/complex
q12h every 12 hours
QT time from the beginning of the QRS complex to the end of the 
Tw a v e
QTc corrected QT interval
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
RT-PCR reverse-transcriptase polymerase chain reaction
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analysis Plan
SARS-CoV-1 severe acute respiratory syndrome coronavirus 1
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SBP systolic blood pressure
SoA schedule of activities
SOP standard operating procedure
SRSD single-reference safety document
SToD Study Team on Demand
SUSAR suspected unexpected serious adverse reaction
T4 thyroxine
TBili total bilirubin
TEAE treatment emergent adverse event
THC tetrahydrocannabinol
TIPS transjugular intrahepatic portosystemic shunt
TSH thyroid stimulating hormone
ULN upper limit of normal
US United States
USPI United States Prescribing Information
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potentialCCI
CCI
CCI
PF-07321332 
Protocol C4671010
Final Protocol, 2 5June 2021
PFIZER CONFIDENTIAL
Page 8911.REFERENCES
1WHO Situation Report 51. 11 March 2020 Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2020.
2Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: 
basis for design of anti -SARS drugs. Science. 2003;300:1763 -7.
3Investigator’s Brochure, PF -07321332. ( June 2021)
4Ritonavir [package insert]. North Chicago, IL: AbbVie Inc; 2017. Available from: 
https://ww w.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf. Accessed: 
24 June 2021.
5US Department of Health and Human Services, Food and Drug Administration, Center 
for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 
Guidan
ce for industry : pharmacokinetics in patients with impaired hepatic function: 
study  design, data anal ysis and impact on dosing and labeling. Rockville, MD: US 
Department of Health and Human Services;  May  2003. Available from: 
https://www.fda.gov/regulator y-information/search -fda-guidance -
documents/pharmacokinetics -patients- impaired -hepatic -function -study -design- data-
analysis-and-impact- dosing -and. Accessed: 24 June 2021.
